CD4+ T cell responses to interleukin-2 administration in HIV-infected patients are directly related to the baseline level of immune activation.

Autor: Sereti I, Sklar P, Ramchandani MS, Read SW, Aggarwal V, Imamichi H, Natarajan V, Metcalf JA, Kovacs JA, Tavel J, Davey RT, Dersimonian R, Lane HC

Publikováno v: Journal of Infectious Diseases; 9/1/2007, Vol. 196 Issue 5, p677-683, 7p

Preparing better: Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) therapeutics trials lessons learned: A call to the future.

Autor: Adam SJ; Foundation for the National Institutes of Health, North Bethesda, MD, USA., Buchman TG; Critical Care Center, Emory University School of Medicine, Atlanta, GA, USA., Currier JS; Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA., Draghia-Akli R; The Janssen Pharmaceutical Companies of Johnson & Johnson, Titusville, NJ, USA., Fessel JP; National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA., Higgs ES; National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA., Hughes EA; Teva Pharmaceuticals, Parsippany, NJ, USA., LaVange L; Biostatistics, Gillings School of Global Public Health at the University of North Carolina at Chapel Hill, NC, USA., Menetski JP; Foundation for the National Institutes of Health, North Bethesda, MD, USA., Read SW; National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA., Rosenberg Y; National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Tressler R; National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA.

Publikováno v: Journal of clinical and translational science [J Clin Transl Sci] 2024 Oct 15; Vol. 8 (1), pp. e150. Date of Electronic Publication: 2024 Oct 15 (Print Publication: 2024).

Immune mechanisms of protection against Mycobacterium tuberculosis -centers.

Autor: Dang Q; Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, United States., Eichelberg K; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, United States., Vázquez-Maldonado N; Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, United States., Boggiano C; Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, United States., Leitner WW; Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, United States., Ramachandra L; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, United States., Deckhut-Augustine A; Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, United States., Read SW; Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, United States.

Publikováno v: Frontiers in immunology [Front Immunol] 2024 Oct 08; Vol. 15, pp. 1429250. Date of Electronic Publication: 2024 Oct 08 (Print Publication: 2024).

Developing tuberculosis vaccines for people with HIV: consensus statements from an international expert panel.

Autor: Miner MD; Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Hatherill M; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa., Mave V; Johns Hopkins India, Byramjee-Jeejeebhoy Government Medical College Clinical Research Site, Pune, India., Gray GE; South African Medical Research Council, Cape Town, South Africa., Nachman S; Department of Pediatrics, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, USA., Read SW; Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., White RG; Department of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK., Hesseling A; Desmond Tutu Tuberculosis Centre, Stellenbosch University, Stellenbosch, South Africa., Cobelens F; Department of Global Health, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands., Patel S; US Food and Drug Administration, Silver Spring, MD, USA., Frick M; Treatment Action Group, New York, NY, USA., Bailey T; Greater Baltimore Medical Center, Baltimore, MD, USA., Seder R; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Flynn J; Microbiology and Molecular Genetics, University of Pittsburgh Medical Center, Pittsburgh, PA, USA., Rengarajan J; Emory School of Medicine, Emory University, Atlanta, GA, USA., Kaushal D; Texas Biomedical Research Institute, San Antonio, TX, USA., Hanekom W; Africa Health Research Institute, Durban, KwaZulu-Natal, South Africa., Schmidt AC; Gates Medical Research Institute, Boston, MA, USA., Scriba TJ; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa., Nemes E; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa., Andersen-Nissen E; Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Cape Town HIV Vaccine Trials Network (HVTN) Immunology Laboratory, Cape Town, South Africa., Landay A; Rush Medical Center, Chicago, IL, USA., Dorman SE; Department of Medicine, Medical University of South Carolina, Charleston, SC, USA., Aldrovandi G; Department of Pediatrics, University of California, Los Angeles, CA, USA., Cranmer LM; Emory School of Medicine, Emory University, Atlanta, GA, USA., Day CL; Emory School of Medicine, Emory University, Atlanta, GA, USA., Garcia-Basteiro AL; ISGlobal, Hospital Clínic Universitat de Barcelona, Barcelona, Spain; Centro de investigação de Saúde de Manhiça, Maputo, Mozambique., Fiore-Gartland A; Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Mogg R; Takeda Pharmaceutical Company, Cambridge, MA, USA., Kublin JG; Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Gupta A; Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Churchyard G; The Aurum Institute, Johannesburg, South Africa; School of Public Health, University of Witwatersrand, Johannesburg, South Africa; Department of Medicine, Vanderbilt University, Nashville, TN, USA. Electronic address: gchurchyard@auruminstitute.org.

Publikováno v: The lancet. HIV [Lancet HIV] 2022 Nov; Vol. 9 (11), pp. e791-e800. Date of Electronic Publication: 2022 Oct 11.

Accelerating Coronavirus Disease 2019 Therapeutic Interventions and Vaccines-Selecting Compounds for Clinical Evaluation in Coronavirus Disease 2019 Clinical Trials.

Autor: Buchman TG; Biomedical Advanced Research and Development Authority (BARDA), Office of Assistant Secretary for Preparedness and Response, U.S. Department of Health and Human Services, Washington, DC., Draghia-Akli R; The Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, PA., Adam SJ; Foundation for the National Institutes of Health, North Bethesda, MD., Aggarwal NR; National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD., Fessel JP; National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD., Higgs ES; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD., Menetski JP; Foundation for the National Institutes of Health, North Bethesda, MD., Read SW; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD., Hughes EA; Novartis Pharma AG, Basel, Switzerland.

Publikováno v: Critical care medicine [Crit Care Med] 2021 Nov 01; Vol. 49 (11), pp. 1963-1973.